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Post-Transfusion Haemolytic 
Reactions
Jolanta Korsak and Anna Piotrowska
Abstract
Haemolytic post-transfusion reaction is caused by accelerated destruction of 
erythrocytes by immunological incompatibility between the donor and the recipi-
ent. It also occurs for non-immunological reasons: thermal, osmotic or mechanical 
damage and bacterial infection. Haemolysis can be endogenous (usually acute) 
and exogenous with macrophages in the reticuloendothelial system of spleen or 
liver (delayed). The pathophysiology: antibody binding erythrocyte antigens, 
antibody-coated erythrocytes interaction with monocytes/macrophages activating 
phagocytosis or antibody-dependent cytotoxicity and the production of inflamma-
tory mediators. Antibodies destroying transfused blood cells are called clinically 
relevant antibodies that are active in vitro at 37°C. An interesting mechanism is the 
“bystander immune cytolysis”.
Keywords: haemolytic reaction, haemolysis, transfusion reaction, HTR
1. Introduction
Haemolytic transfusion reaction (HTR) is the result of accelerated destruc-
tion of red blood cells. The most common cause is immunological incompatibility 
between a donor and a blood recipient. It is mainly haemolysis that is responsible 
for the destruction of transfused donor blood cells by antibodies present in the 
recipient, but in rare cases, destruction may be caused in recipient blood cells 
by donor antibodies present in transfused plasma or platelet concentrate [1]. 
Haemolysis may also occur due to non-immunological reasons, such as thermal, 
osmotic or mechanical damage to the transfused blood; bacterial infection or 
extremely rare and blood transfusion from a donor with congenital haemolytic 
anaemia due to deficiency of glucose-6-phosphate dehydrogenase [2].
2. The incidence of haemolytic transfusion reactions
Currently, the incidence of haemolytic transfusion reactions is difficult to 
estimate. Most data come from retrospective studies that do not include reactions 
not reported by clinicians. In contrast, prospective studies also contain errors due to 
reaction symptoms often remaining unrecognised or masked by associated diseases, 
for example, bleeding or liver disease [1]. The frequency of reporting haemolytic 
transfusion reactions may also depend on other factors, such as patient population, 
transfusion response reporting system and medical staff education. Historical 
research results indicate that the frequency of haemolytic transfusion reactions falls 
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between 1:10,000 and 1:50,000 transfused blood components [3, 4]. In contrast, 
the incidence for patients receiving a transfusion is estimated to be higher (about 
1:500–1:800 patients) because most recipients receive more than one blood unit. 
It is worth noting that the estimation of the frequency of haemolytic reactions 
depends on the number of transfusions in a given centre. Thus, in large clinical cen-
tres, where severely ill patients are treated, more of these events are recorded [4]. A 
report issued by the Quebec Haemovigilance System covering 5 years of observation 
described 47 ABO incompatibility reactions, 55 cases of acute haemolytic transfu-
sion reaction and 91 cases of delayed transfusion reaction in reference to 7059 all 
reported transfusion reactions. It was estimated that the frequency of reactions 
resulting from the ABO incompatibility was 1:27,318, acute haemolytic transfusion 
reactions 1:14,901 and delayed haemolytic transfusion reactions 1:9313 per unit of 
transfused red blood cell concentrate [5].
The most common reaction among the acute (approximately 30%) was haemol-
ysis resulting from ABO incompatibility [5]. In the annual report Serious Hazards 
of Transfusion (SHOT), published in England, in 2017, 42 haemolytic transfusion 
reactions were reported in reference to 3230 of all reactions observed following 
transfusion of blood components, of which 13 cases of acute haemolytic transfusion 
reaction and 29 cases of delayed haemolytic reaction (including 6 cases of hyperhe-
molysis) were reported. The number of reported cases of delayed haemolytic trans-
fusion reaction was higher than in 2016, but comparable with previous years [6]. 
Factors that can affect the increase in the number of delayed haemolytic reactions 
include correctness in carrying out serological tests, longer survival of patients after 
transfusions and an increase in the number of transfused blood components. Since 
most patients receive more than one unit of red blood cell concentrate, the esti-
mated incidence of delayed haemolytic transfusion reactions is from 1:854 to 1:524 
per patient who has been transfused and is higher than per transfused unit [7]. In 
the population, delayed haemolytic transfusion reactions occur with a frequency of 
1.69/100,000 per year [7].
3. Mechanisms of haemolytic transfusion reactions
Red blood cells undergo haemolysis in the intravascular mechanism, in blood 
or extravascular vessels, that is, organs involving cells of the reticuloendothelial 
system, primarily spleen and/or liver. Clinically significant differences between 
the above mechanisms of red blood cells destruction are based on the time of onset 
of haemolysis and the destruction rate of red blood cells. Intravascular haemolysis 
is characterised by the destruction of red blood cells at a rate of about 200 ml of 
transfused cells within 1 h of transfusion. It is manifested by a rapid decrease in 
haemoglobin, haemoglobinemia and haemoglobinuria and can potentially be life 
threatening [2]. In contrast, extravascular haemolysis is less dramatic, with a rate of 
destruction of red blood cells of approximately 0.25 ml/h/1 kg of recipient’s body 
weight. For example, for 70 kg recipient, about 18 ml of transfused red blood cells 
are destroyed per hour. However, it is worth noting that despite the low intensity 
of haemolysis, the survival time of red blood cells after transfusion is significantly 
reduced [2]. In general, intravascular haemolysis is called as an early acute hae-
molytic transfusion reaction. It can occur during transfusion or up to 24 h after 
transfusion of red blood cells. In comparison extravascular haemolysis is called 
delayed haemolytic transfusion reaction and usually occurs 24 h or days after the 
end of the transfusion. The quoted breakdown of reactions is somewhat artificial, 
because the symptoms associated with haemolytic reactions sometimes overlap [1]. 
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The occurrence and severity of individual clinical symptoms can vary widely and 
are often non-specific [1, 8].
Red blood cell transfusion can also stimulate the production of alloantibodies 
without the occurrence of haemolysis. This phenomenon is called delayed serologic 
transfusion reaction (DSTR) and should be differentiated from delayed haemolytic 
transfusion reaction [9].
3.1 Intravascular haemolysis
Most often intravascular haemolysis is the result of the destruction of red blood 
cells by the complement system, stimulated by the presence of alloantibodies or 
autoantibodies. Among alloantibodies, such haemolysis is induced by anti-A and 
anti-B, rarely anti-Jka, anti-Jkb, anti-Vel, anti-P, anti-Lea and very unique antibod-
ies with other specificities [10, 11]. In all these cases, haemolysis takes place via the 
classical pathway of complement activation. Its occurrence and severity, in addition 
to the class of antibodies, is also affected by the number of antigenic determinants 
with which the antibodies react. The reaction is most severe in the case of antigens 
A and B, because their number is estimated at about 5 × 105 per cell [12, 13]. In 
contrast, the presence of antigens from the Rh, Kell, Kidd and Duffy systems on the 
surface of red blood cells is determined in the range of 103–104 per cell [12]. Table 1 
shows the number of antigenic determinants on the cell surface for selected red 
blood cell antigens.
Antibodies combined with antigens by triggering the complement cascade lead 
to cell lysis. This mechanism is called the classic pathway for complement activation 
and is shown in Figure 1.
The starting point is the antigen-antibody complex present on the surface of 
the cell membrane [14, 15]. Antibodies of the IgM and IgG class (outside the IgG4 
subclass) bind the C1q protein in the initial stage of activation. The condition for 
complement activation is the binding of the C1q molecule by two Fc fragments of 
adjacent IgG antibodies or by one IgM molecule. It should be noted here that the 
IgM class is more efficient in starting the process of complement activation than the 
IgG class [2, 15]. The C1qrs complex is created and activates the C2 and C4 compo-
nents and their distribution into C2a and C2b as well as C4a and C4b. The C4b2a 
Blood group 
system
Antigens The number of antigenic determinants on the surface of the cell 
membrane
ABO A1 8.5 × 10
5
A2 2.5 × 10
5
B 7.5 × 105
Rh D 1–2 × 105
C 7–8 × 104
e 1.8–2.4 × 104
Kell K 6.1 × 103
Duffy Fya 1.7 × 104
Kidd Jka 1.4 × 105
MNSs S 1.2 × 104
Table 1. 
Number of antigenic determinants on the cell surface of the red blood cell (according to [12, 13]).
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complex has proteolytic properties and is called C3 convertase. Convertase breaks 
down molecules of C3 into C3a, C3b, C3c and C3d. The C3b and C3d components 
bind with the red blood cell membrane and in many cases the complement cascade 
process ends. In other cases, the C3b component activates C5 and C5a and C5b 
are formed. C5b binds to C6, then to C7. This creates a complex of three C5b-6-7 
particles, which is partially incorporated into the cell membrane and further binds 
C8. The C5b-8 complexes create holes in the cell membrane that increase when 
exposed to the C9 component. The C5B-C9 complex called membrane attack com-
plex (MAC) creates pores in the cell membrane of a red blood cell that are 1/700 
of its size. Haemoglobin escapes from the cells into the plasma, and the effects of 
haemolysis are visible macroscopically in the plasma of the blood sample [15].
The alternative path of complement activation and the lectin path of comple-
ment activation do not play a role in the destruction of red blood cells. Although the 
mechanism of the lectin route may be the reason for the in vivo ineffectiveness of 
the use of monoclonal and recombinant antibodies, which are thus eliminated from 
the body before they fulfil their function, for example, anti-D Ig for prevention 
purposes in RhD maternal-foetal conflict [16].
However, the complement system does not work specifically. The safety of body 
cells is enabled by factors that regulate complement activity present in plasma and 
on cells of various tissues, including red blood cells. Membrane inhibitor of reactive 
lysis (MIRL) (CD59) and decay accelerating factor (DAF) (CD55) are essential to 
protect red blood cells from haemolysis. The expression of these membrane inhibi-
tors is associated with Cromer group system and CD59. On blood cells with the 
Cromer mull phenotype, known as Inab, DAF inhibitor expression is absent [17, 18]. 
DAF regulates C3a-converting activity. MIRL inhibits membrane attack complex 
[15, 17]. Lack of these particles may increase the susceptibility of red blood cells to 
intravascular haemolysis due to complement activation [19].
3.2 Extravascular haemolysis
In a situation in which, despite activation of the complement system, through 
antigen-antibody reaction, there is no intravascular haemolysis, red blood cells with 
detectable C3b component remain in the circulation. This kind of mechanism of 
red blood cell destruction occurs for IgG antibodies with complement system [13]. 
They may interact with CR1 and CR3 receptors on macrophages and consequently 
undergo phagocytosis. Most of the cells coated by the complement C3b component are 
destroyed by liver macrophages, that is, by Kupffer cells, while the cells coated with 
antibody molecules are mainly destroyed by spleen macrophages. They have surface 
receptors that recognise antibody classes and subclasses, and complement components, 
Figure 1. 
The classic pathway for complement.
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of which the Fc R1 receptor is specific for red cells coated with antibodies [1]. Blood 
cells connected to this receptor are destroyed in the process of antibody-dependent 
cytotoxicity. Red blood cells can be absorbed and completely “digested” inside the 
macrophage. They can also be partially absorbed and then the integrity of the cell 
membrane is disturbed by the loss of proteins and lipids, which changes its osmotic 
properties. Such a blood cell, after being released from the macrophage, circulates 
in the blood as a spherocyte, whose survival is short. The macrophage cytotoxins are 
another mechanism that plays a role in the destruction of red blood cells. As a conse-
quence of antibody-dependent cell-mediated cytotoxicity (ADCC) haemoglobinemia 
and haemoglobinuria may occur similarly to intravascular haemolysis, although the 
antibodies that caused it do not bind complement components.
4.  Mediators of inflammatory reactions in haemolytic transfusion 
reactions
Receptors for complement activation products C3a and C5a are found on many 
cells: monocytes, macrophages, neutrophils, platelets, endothelium and smooth 
muscle. Their release causes an increase in the concentration of oxygen radicals, 
leukotrienes, nitric oxide and cytokines. The increase in cytokine release may also 
be due to the interaction of Fcγ R1 receptors with IgG molecules associated with 
red blood cells. Udani et al. [20] showed in vitro that in the case of ABO incom-
patibility, monocytes are directly involved in the formation of acute haemolytic 
transfusion reaction [15]. Incompatible red blood cells reduce CD14 expression and 
increase CD44 expression on monocytes in whole blood. After 24 incubations with 
incompatible red blood cells, monocytes show a significant increase in CD44 levels. 
The results of these studies indicate a critical role of monocyte activation in the 
development of intravascular haemolytic transfusion reaction [15].
In ABO incompatibility, in which anti-A, anti-B and anti-AB antibodies activate 
complement leading to intravascular haemolysis, a large amount of tumour necrosis 
factor-α (TNF) and interleukins CXCL8 (IL-8) and CCL2 are released into the 
plasma (MCP-1) [19–21]. TNF-α is released first, its elevated concentration is already 
detected within first 2 h. It carries a pro-inflammatory potential that is responsible 
for fever, leukocyte activation, stimulation of procoagulant activity, increased anti-
body production and vascular wall permeability [22]. TNF-α also stimulates endo-
thelial cells to synthesise adhesion molecules and chemotactic cytokines [22]. CXCL8 
and CCL2 produced in the blood during ABO incompatibility will appear later than 
TNF-α in very high concentrations. CXCL8 primarily activates neutrophils, which 
leads to the accumulation of leukocytes in the lung vessels of small diameter and 
damage to the endothelium of blood vessels and their higher permeability [1, 12]. 
CCL2 is mainly a chemotactic and activating factor for monocytes [1, 12].
In incompatibility, in which non-complement IgG antibodies cause extravascu-
lar haemolysis, cytokines belonging to two categories differing in response rates are 
produced: (1) synthesised at a concentration higher than 1 μg/ml within 24 h and 
(2) synthesised at a concentration of about 100 pg/ml. Low concentration cytokines 
include IL-1β, IL-6 and TNF-α. CXCL8 concentration is similar to that in intravas-
cular haemolysis, whereas TNF-α is synthesised at low concentration, estimated 
at <100 pg/ml [1, 2]. IL-1ra (receptor antagonist) is produced in extravascular 
haemolysis, which is an IL-1 receptor antagonist. Its presence to some extent affects 
some clinical differences between extravascular and intravascular haemolysis [23]. 
IL-1β concentration and IL-6 produced by monocytes in response to red blood 
cells coated with IgG antibodies increase progressively within 24 h to a concentra-
tion of 100 pg/ml. Since IL-1β and IL-6 affect proliferation and differentiation 
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of β-lymphocytes, the synthesis of these two cytokines enhances the synthesis 
of allo- and autoantibodies, which are often involved in the formation of delayed 
haemolytic transfusion reaction [1, 24, 25].
5. Complications of haemolytic transfusion reactions
5.1  Disseminated intravascular coagulation associated with haemolytic 
transfusion reaction
The key pathogenetic phenomenon in DIC is excessive thrombin generation in 
the tissue factor (TF)-dependent pathway and activated factor VII (FVIIa-activated 
factor VII) [26]. In the pathogenesis of DIC, interactions between the blood coagu-
lation system and mediators of the inflammatory response are also of great impor-
tance [27]. Proinflammatory cytokines affect blood coagulation and fibrinolysis, 
for example, TNF-α and IL-1 increase TF expression and inhibit thrombomodulin 
(TM) expression on vascular endothelial cells [28]. On the one hand, these pro-
cesses lead to the production of a large amount of thrombin that converts fibrinogen 
to fibrin. Fibrin creates blood clots in the light of small vessels trapping the plate-
lets. If the activation of coagulation is not timely inhibited, the resulting clots will 
block the blood supply to vital organs, which will be manifested in their failure. On 
the other hand, the formation of a large amount of blood clots will “consume” blood 
coagulation factors and platelets, which will manifest as a haemorrhagic diathesis. 
In addition, their degradation products (fibrinogen/fibrin degradation products 
(FDP)) resulting from the breakdown of fibrinogen and fibrin exhibit anticoagu-
lant properties, inhibit platelet function, act as cytotoxic vascular endothelium and 
increase capillary permeability, further disrupting haemostasis mechanisms [26].
Clinically, this is manifested by unexpected bleeding and/or a decrease in blood 
pressure. The course is acute, dynamic, with thrombocytopenia, increased concen-
tration of fibrin degradation products, prolonged prothrombin time (PT), extended 
partial thromboplastin time after activation (activated partial thromboplastin time 
(APTT)) and hypofibrinogenaemia. Table 2 presents the point algorithm for the 
diagnosis of acute disseminated intravascular coagulation.
However, this complication is rare and predominantly accompanies intravascu-
lar haemolysis, but in recipients who have received non-compliant blood in the ABO 
system, it occurs even in 25% of cases [1].
5.2 Hypotension and shock
Hypotension occurs in about 1 in 10 cases of intravascular haemolytic trans-
fusion reaction, but is also sometimes observed in extravascular haemolysis. 
Complement activation appears to be the most important determining factor 
in these cases. During the haemolytic reaction, C3a, C4a, C5a and C5a-des-arg 
anaphylatoxins are released. Furthermore, consumption of a C1-esterase inhibitor 
contributes to the activation of the kinin pathway associated with the release of bra-
dykinin [32]. In addition, tumour necrosis factor (TNF) and interleukin-1 (IL-1), 
released by phagocytes during haemolytic transfusion reaction may also contribute 
to hypotension and shock [32].
5.3 Impaired renal function
Impaired renal function is observed in both intravascular and extravascular 
haemolytic transfusion reactions, although definitely more frequently in the case of 
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intravascular. The severity of this abnormality varies greatly—from asymptomatic 
increase in urea (BUN) and serum creatinine up to complete anuria. Concomitant 
hypotension and intravascular coagulation syndrome may increase renal impair-
ment. Blood clots that form in the renal arterioles cause cortical kidney attacks. 
Haemoglobin released from red blood cells also reacts nephrotoxically with nitric 
oxide (NO), damaging the epithelial cells of the renal tubules and the stroma that 
remains after their breakdown [33, 34].
Intravascular haemolysis modulates blood pressure and local blood flow through 
changes in the metabolism of the physiological vasodilator—nitric oxide (NO). NO 
can bind to thiol groups and haemoglobin haeme [35]. The connection of NO with 
haeme Fe2+ impairs oxygen transport through Hb. The presence of O2 leads to oxida-
tion of NO to NO3 and oxidation of Fe
2+ to Fe3+ and the formation of methaemoglo-
bin. The interaction between Hb and NO is regulated by the allosteric transition of 
haemoglobin R (oxyHb) to the T form (deoxyHb). In oxyHb, cysteine is exposed 
at position 93 of the haemoglobin amino acid chain (Cys 93β). It is known that a 
significant proportion of NO does not immediately bind to HbFe2+ heme, instead 
it binds to cysteine, resulting in the formation of the S-nitrosothiol derivative Hb 
(SNO-Hb). This process is reversible, so SNO-Hb releases NO, which is transported 
to endothelial receptors, where it participates in the regulation of vascular wall tone 
and blood flow. In the case of haemolysis of red blood cells, the free haemoglobin 
released from them reacts with NO much faster and more strongly than Hb inside 
cells [35]. The effect of intravascular haemolysis described above may be very simi-
lar to the side effect caused by transfusion of first-generation stromal haemoglobin 
solutions. This has been tested for its use as a substitute for red blood cells. It had 
vasoconstrictive and, as a result, hypertensive effect. This effect is largely attributed 
to the binding nitric oxide by free haemoglobin (NO) [36].
6. Clinical symptoms of transfusion haemolytic reactions
Intravascular haemolysis is accompanied by haemoglobinaemia and usu-
ally also haemoglobinuria, whereas extravascular haemolysis can only be 
Test Result Score
Platelet count (×109/l) >100 0
>50, ale ≤ 100 1
≤50 2
Concentration of fibrinogen/fibrin degradation markers (FDP; 
D-dimery)
Normal 1
Moderate 2
Growth significant 
increase
3
Prothrombin time extended o < 3 s 0
o ≥ 3 s, ale < 6 s 1
o ≥ 6 s 2
Fibrinogen concentration (g/l) >1.0 0
≤1.0 1
DIC acute diagnosis ≥5
Table 2. 
Point algorithm for the diagnosis of acute disseminated coagulation Intravascular [29–31].
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accompanied by anaemia. In both cases, the patient’s serum bilirubin increases, 
but it depends on the degree of haemolysis as well as liver function [1]. Elevated 
LDH is always observed with intravascular haemolysis, not always with extra-
vascular haemolysis. Reduced haptoglobin levels usually occur in both types 
of haemolysis. Drop in blood pressure is much more common in patients with 
intravascular than extravascular haemolysis. Renal failure and DIC are also more 
commonly associated with intravascular haemolysis. Some patients may experi-
ence organ failure such as the pancreas, heart and even multiple organ failure that 
threatens the patient’s life.
In unconscious patients and patients under general anaesthesia, it may be 
difficult to recognise a haemolytic transfusion reaction, as some symptoms may 
go unnoticed (e.g. pain and nausea). Pain, which is described as a symptom of 
haemolytic reactions, is located at the puncture site, back, chest, groin and head. 
The occurrence of pain in the haemolytic transfusion reaction is not clear. It is 
probably the result of direct stimulation of nociceptive nerves in perivascular tissue 
by bradykinin, which, in turn, is released during sudden activation of complement 
[37]. Clinical manifestations are shown in Table 3.
7. Causes of haemolytic transfusion reactions
7.1 Haemolytic transfusion reactions caused by alloantibodies
The most common cause of haemolytic transfusion reactions is the immunologi-
cal destruction of red blood cells resulting from the reaction of antibodies in the 
recipient’s blood and the antigens present on the transfused donor’s blood cells to 
which these antibodies are made.
Antibodies capable of destroying transfused blood cells are called clinically 
relevant antibodies, and the transfusion reaction in the event of immunological 
incompatibility depends on: (1) specificity of antibodies; (2) thermal amplitude 
of the antibodies; (3) IgG classes and IgG subclasses; (4) number, density and 
spatial configuration of antigenic sites on red blood cells; (5) the ability of anti-
bodies to activate the complement system; (6) plasma concentrations of antibod-
ies and (7) volumes of transfused red blood cells. A very important feature of all 
antibodies responsible for causing a haemolytic transfusion reaction is its in vitro 
activity at 37°C.
Initial symptoms of haemolytic transfusion 
reactions
Complications
Intravascular haemolysis
Nausea or vomiting
Ache
Dyspnoea
Decrease in RR and/or tachycardia
Dark urine
Kidney failure
Disseminated intravascular coagulation (DIC)
Extravascular haemolysis
Fever and/or chills
Nausea or vomiting
Ache
Dyspnoea
Kidney failure
disseminated intravascular coagulation (DIC)
Table 3. 
Initial symptoms of haemolytic transfusion reactions.
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Antibodies detected at a lower temperature are not considered clinically rel-
evant, for example, anti-A1, anti-M and anti-P1, whose optimal reaction is usually 
at low temperature, but if detected at 37°C, they can cause destruction of red blood 
cells with the appropriate antigen. They then become clinically significant.
Features of antibodies (specificity, class and heat amplitude) and antigens (den-
sity of antigenic sites and their distribution) against which the antibodies directed 
are interconnected. In different people, antibodies with a particular specificity most 
often occur in the same class of immunoglobulins and have a similar heat ampli-
tude, for example, anti-A, anti-B and anti-AB from the ABO system often belong 
to both IgM and IgG classes, they bind complement and have an extended thermal 
amplitude of up to 37°C.
A and B antigens are highly immunogenic. Anti-A, anti-B and anti-AB anti-
bodies are involved in causing an early intravascular transfusion reaction, and 
transfusion of incompatible blood in the ABO system poses a threat to the recipi-
ent’s life, especially when group A red blood cells are transfused to a patient with 
group O. Sixty-one (61%) of all haemolytic transfusion-related fatal reactions are 
associated with the ABO incompatibility [38, 39]. A contrasting example is the Lua 
antigen and anti-Lua antibodies. They are usually IgM molecules, are rarely active 
at 37°C and usually do not bind complement. Lua antigens have uneven distribu-
tion on red blood cells and are weakly immunogenic. No cases of acute haemolytic 
reaction caused by anti-Lua antibodies have been reported, delayed transfusion 
haemolytic reaction is rare and occurs only in mild form.
Not all detectable alloantibodies that react with red blood cells can cause a 
haemolytic reaction. The specificity of the antibodies potentially responsible for 
intravascular and extravascular haemolysis is shown in Table 4.
Similar reactions to anti-A and anti-B come from anti-PP1P
k, anti-P1 and 
anti-Vel. Other antibodies cause intravascular haemolysis, but sometimes they 
may be accompanied by intravascular haemolysis. Such reactions were observed in 
the following blood group systems: Rh, MNSs, Lutheran, Kell, Duffy, Diego and 
Lewis. The mechanism of appearance of intravascular symptoms has not been fully 
explained, because although some of the antibodies bind complement components, 
Blood group 
system
Intravascular haemolysis Extravascular 
haemolysis
ABO, H Anti-A, -B, -AB, -H in the Bombay phenotype
Rh All
Kell Anti-K All
Kidd Anti-Jka Anti-Jka, -Jkb, -Jk3
Duffy Anti-Fya, -Fyb
MNS Anti-M, -S, -s, -U
Lutheran Anti-Lub
Lewis Anti-Lea
Cartwright Anti-Yta
Vel Anti-Vel
Colton Anti-Coa
Dombrock Anti-Doa, -Dob
Table 4. 
Specificity of selected antibodies associated with haemolytic transfusion reactions.
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their reactions end with C3 components. Only in the case of rare haemolytic reac-
tions due to anti-Lea it was shown that the coated cells are destroyed by the spleen 
macrophages very slowly and in the event of transfusion of large volumes of red 
blood cells, they become inefficient. Then intravascular haemolysis coincides with 
visible haemoglobinuria [40, 41]. Interesting clinical point of view are antibodies 
from the Kidd system. They activate the complement system to the stage of binding 
of the C3b component, causing extravascular haemolysis. However, the symptoms 
in some recipients, or the occurrence of a reaction already during a blood transfu-
sion and haemoglobinuria, indicate that the destruction of blood cells also takes 
place inside the vessel. In the laboratory setting, anti-Jka antibodies are called 
“insidious” antibodies because they are often difficult to detect due to their low 
concentration, and yet they can cause a severe haemolytic complication [41].
Patients with antibodies found to be clinically insignificant may theoretically be 
given a blood transfusion from a donor with the antigen to which they are directed. 
In clinical practice, however, such antibodies can sometimes destroy donor blood 
cells. Therefore, if possible, blood without this antigen should be selected [41].
Another cause for haemolytic transfusion reaction may be a secondary immune 
response in patients who have developed alloantibodies during previous transfu-
sions of blood components or pregnancy. This is called delayed haemolytic trans-
fusion reaction (DHTR) in which current blood transfusion stimulates memory 
lymphocytes and stimulates the production of alloantibodies directed at incompati-
ble antigen found on transfused blood cells [21, 42]. In approximately 50% of cases, 
alloantibodies produced after transfusion or pregnancy cease to be detected after 
a few months, and this period of time depends on the specificity of the antibodies 
and the individual characteristics of the immune system. Schonewille et al. found 
that, using current laboratory methods, 25% of red blood cell antibodies become 
indeterminate on average after about 10 months from production [43]. Therefore, 
pre-transfusion tests may not always detect the presence of antibodies. Antibodies 
stimulated for synthesis may cause symptoms of haemolysis after 3–10 days, usually 
very mild and their presence can be detected after 10–21 days. Table 5 presents fea-
tures of delayed haemolytic transfusion reaction and the time of their occurrence.
Antibodies that cause a delayed haemolytic transfusion reaction are IgG mole-
cules that are binding or non-binding for complementary components. Their speci-
ficity is most often directed to the antigens of the Rh, Kidd, Duffy, MNS and Kell 
systems [14]. In approximately 11% of cases, more than one antibody specificity is 
Time (days) Occurrence Explanation
0 Negative pre-transfusion test Antibody titres below detection threshold
1 Red blood cell transfusion
3–10 Clinical symptoms of haemolysis Acceleration of transfused blood cells 
destruction
10–21 Post-transfusion testing of blood samples: 
DAT and screen of antibodies positive
Increase in antibody titre; donated blood 
cells coated with antibodies
>21 DAT can be negative Destruction of donor blood cells in 
reticuloendothelial system and/or liver
>21–300 DAT may be positive, eluate testing 
may show presence of alloantibodies or 
panagglutination
Alloantibodies not specifically associated 
with autologous red blood cells or 
produced warm antibodies
DAT—direct antiglobulin test.
Table 5. 
Features of late hemolytic transfusion reaction and time of their occurrence [21].
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detected. In rare cases, the result of transfusion alloimmunity in DHTR may be the 
production of autoantibodies (warm IgG autoantibodies or cold autoagglutinins). 
This phenomenon occurs in patients with sickle cell disease [44–46].
7.2  Haemolytic transfusion reactions due to passive transmission of 
alloantibodies in blood components or in blood products
Transfusion of plasma, platelet or granulocyte concentrate from donors 
incompatible in the ABO system with the recipient may lead to acute haemolytic 
transfusion reaction and even death. The severity of the reaction depends on the 
titre of anti-A and/or anti-B antibodies in the transfused plasma or in the blood 
component containing the plasma, and on its volume [47–49]. Tests on the ABO 
system titre in group O apheresis concentrates of platelets show that 26% of samples 
have an anti-A or anti-A, B antibody titre of 64 or higher. This concentration may be 
responsible for causing a haemolytic reaction [50]. In turn, the results of studies by 
Coolig et al. [51] carried out in pooled platelet concentrates of whole blood groups 
showed that 60% of them had anti-A titres of at least 64 [51]. Repeated transfu-
sions of ABO incompatible platelet concentrate may lead to accumulation of anti-A 
antibodies in the recipient’s plasma, which may result in severe haemolytic reactions 
[52]. Unfortunately, despite many studies, it has not been possible to determine 
the critical titre of anti-A and/or anti-B antibodies that would be safe in the event 
of transfusion of ABO incompatible platelet concentrates, and in many countries, 
proprietary haemolysis prevention programs have been developed for recipients of 
incompatible platelets [48–50, 53].
Haemolytic transfusion reactions due to passively transferred anti-A and/or 
anti-B antibodies have also been observed in patients after intravenous immu-
noglobulin administration [54]. Spath et al. [55] analysed reports available in 
the literature describing cases of haemolysis in patients treated with intravenous 
immunoglobulins [55]. They showed that the haemolytic reaction is induced by IgG 
anti-A/B antibodies present in immunoglobulin products. The reaction generally 
occurs in high-dose IVIG recipients [55].
7.3 Haemolytic reaction associated with the “bystander immune cytolysis”
The haemolytic transfusion reactions may have a different immunological origin 
than the reactions of antibodies in the recipient’s blood and the antigen present 
on the donor’s blood cells. This additional mechanism occurs when recipient’s red 
blood cells are destroyed by a reaction called “bystander immune cytolysis”. It is 
defined as the immunological destruction of red blood cells by antibodies whose 
specificity corresponds to antigens found on other cells/blood cells (e.g. HLA anti-
gens found on leukocytes and plasma proteins), while red blood cells are only close 
to this immunological “confusion” [56]. They are destroyed by the complement 
system, although they did not participate directly in the antigen-antibody reaction. 
One of the reasons for this haemolytic reaction is the binding of the C567 comple-
ment complex, activated in an immune reaction, to the membrane of red blood 
cells not participating in the reaction but located in the vicinity [56]. Blood cells are 
destroyed as a result of the activation of the binding of the remaining components 
of C8 and C9 complement and the formation of the MAC complex on the blood 
cells [56]. The mechanism of “bystander” haemolysis is similar to the destruction 
of blood cells in patients with paroxysmal nocturnal haemoglobinuria [57, 58]. A 
characteristic feature of the cell membrane of these blood cells is the lack or weak 
expression of the CD55 (DAF) and CD 59 (MIRL) proteins, which are complement 
inhibitors. This makes the subject more susceptible to haemolysis. It was found that 
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when red blood cells became the “bystander” of leukocyte reactions and antibodies 
directed to them, they underwent haemolysis. The reaction of anti-HLA antibodies 
with leucocytes caused complement activation, which resulted in haemolysis of 
the patient’s red blood cells sensitive to the complement [59]. It is noteworthy that 
in patients with a haemolytic reaction associated with the immune cytolysis of the 
“bystander” not only transfused red blood cells but also autologous blood cells of 
the patient were destroyed.
8. Differentiation
Early haemolytic transfusion reactions should be differentiated with septic 
shock due to bacterial contamination of the blood component, as well as anaphy-
laxis and bleeding. In addition, immune haemolysis of nocturnal paroxysmal hae-
moglobinuria or autoimmune anaemia should also be considered. The cause of an 
early haemolytic reaction may also be congenital haemolytic anaemia, for example, 
glucose-6-phosphate dehydrogenase deficiency or microangiopathic haemolytic 
• Alloantibodies responsible for haemolysis
• Delayed serological transfusion reaction
• Autoimmune haemolytic anaemia
• Cold agglutinins disease
• Non-immune haemolysis
 ○ use of inappropriate fluids
 ○ improper storage of blood components
 ○ defects in the blood-heating devices
 ○ needle diameter too small, haematocrit of transfused red blood cells too high
 ○ an inappropriate method of freezing/thawing red blood cells
 ○ using the wrong infusion pumps
 ○ bacterial infection of blood components
 ○ mechanical damage to blood cells, artificial valves
• Congenital haemolytic anaemia
• Haemoglobinopathies
• Drug-induced haemolysis of red blood cells
• Microangiopathic haemolytic anaemia
 ○ thrombocytopenic thrombosis (TTP)
 ○ haemolytic uremic syndrome
 ○ HELLP syndrome
• Bleeding
• Nocturnal paroxysmal haemoglobinuria
• Polyagglutination
• Infections
 ○ Clostridium perfringens
 ○Malaria
 ○ Babesiosis
Table 6. 
Differential diagnosis of haemolytic transfusion reactions [1].
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anaemia (TTP, HUS and HELLP). In differential diagnosis, attention should also be 
paid to non-immune reasons related to improper blood storage, transfusion of red 
blood cells through a small needle diameter, etc.
Differential diagnosis of delayed haemolytic transfusion reactions includes 
latent sources of infection, autoimmune haemolytic anaemia, cold agglutinin 
disease, nocturnal paroxysmal haemoglobinuria, bleeding, mechanical destruction 
of red blood cells, for example, artificial heart valves and TTP.
It should be noted that an increase in body temperature and white blood cell 
count, typical for DHTR, can be interpreted as a sign of infection. In some patient 
groups, it may be difficult to recognise a delayed haemolytic transfusion reaction. 
Patients with liver failure are a special problem. Haemoglobinemia is not diagnosed 
in the serum of these patients due to jaundice, often direct antiglobulin reaction 
(DTA) is positive and elevated bilirubin and LDH are found.
Another group are patients with absorbing haematomas. They may be similar 
to delayed haemolytic reactions. Elevated unbound bilirubin, LDH and decreased 
haptoglobin are observed. The presence of fibrinogen degradation products from an 
absorbing haematoma can be interpreted as a DIC symptom. DHTR can be identi-
fied in these patients by the presence of antigen on the transfused red blood cells to 
which the antibodies may be directed. Table 6 presents the differential diagnosis of 
haemolytic transfusion reactions.
9. Diagnosis of transfusion haemolytic reactions
If a haemolytic transfusion reaction is suspected, medical personnel should 
immediately stop transfusing a blood component. The blood unit should be checked 
at the patient’s bedside, whether it was properly administered. Often, the clinical 
manifestations of haemolytic reactions are not clear, and the cause of the complica-
tion should be differentiated with bacterial infection. Therefore, prior to conduct-
ing laboratory tests of donor blood, bacteriological examination of the component 
remaining after the transfusion cessation should be conducted.
9.1 Tests carried out in case of suspected early hemolytic transfusion reaction
Laboratory tests—mainly serological—are crucial for the diagnosis of an early 
haemolytic reaction. The type of laboratory tests performed for early transfusion 
haemolytic reactions is shown in Table 7.
The basic serological examination consists of direct antiglobulin testing (DAT); 
determination of blood group and RhD in donor and recipient; repetition of the 
serological compliance test. A test should be performed for the presence of antibod-
ies in the recipient before and after the transfusion. Positive DAT indicates haemoly-
sis of red blood cells of immunisation origin. A negative DAT result does not exclude 
haemolysis, it may mean that the transfused blood cells have been destroyed by 
alloantibodies or the method used is not very sensitive. Alvarez et al. [60] compared 
the sensitivity of DAT performed by technique using monospecific IgG antiglobulin, 
flow cytometry and antibody elution. The study showed that DAT could only indi-
cate 10% of antibody coated cells [61]. Performing DAT in the red blood cell eluate, 
its sensitivity was 1%. Flow cytometry proved to be a similarly sensitive method.
The re-determination of the ABO and RhD blood group of the recipient before 
and after the transfusion and in the donors’ blood will exclude errors in the identifi-
cation of the recipient or blood sample (wrong blood in tube (WBIT)). Test results 
carried out by Biomedical Excellence for Safer Transfusion Working Party of The 
International Society for Blood Transfusion in 10 countries with 62 institutions, 
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which examined a total of 690,000 blood samples, showed that the frequency of 
WBIT is 1 in 165. In two countries, Sweden and Finland, which have implemented 
national identification systems, this frequency was 1 for 1986 samples [61].
All-antibody screening for recipients is generally performed using routine testing 
on standard blood cells. A panel of standard cells should contain clinically impor-
tant antigens in a homozygous form to detect the presence of weak antibodies. The 
test should be performed on serum/plasma samples taken before and after transfu-
sion. If positive results indicate alloantibodies are present, they should be identified. 
Detection of a specific antigen on the donor’s blood cells is the confirmation that the 
detected alloantibodies were responsible for the haemolytic transfusion reaction. 
If negative results are obtained, additional tests should be performed, for example, 
PTA PEG, polybrene test and PTA NaCl test. If negative results persist, the test 
should be repeated after a week and after 2 weeks, as in some patients, the antibod-
ies may have been consumed to destroy transfused incompatible red blood cells.
Laboratory tests that help to differentiate haemolysis include determination of 
free haemoglobin in the blood and urine, haptoglobin and lactate dehydrogenase 
(LDH) and bilirubin. While interpreting the obtained test results, it should be 
kept in mind that haemolysis or shortening the survival time of red blood cells can 
be caused by non-immunological factors, for example, adding hypotonic fluids to 
red blood cells, inefficient heating or freezing devices, etc. [62]. Table 8 presents 
changes in laboratory indicators in transfusion haemolytic reactions [56].
9.2  Tests carried out in case of suspected delayed haemolytic transfusion 
reaction
Laboratory tests show anaemia, increased LDH and bilirubin, decreased hapto-
globin and higher white blood cell counts in post-transfusion haemolytic reactions. 
Bilirubin concentration depends on the severity of haemolysis and liver function.
Laboratory indicators Frequency (%)
Low haptoglobin 92 92
Positive DAT 89*
Increased bilirubin concentration medium/slow 80
The presence of haemoglobin in plasma and/or urine 88 vs. 52**
*Negative DAT mainly associated with HTR in ABO incompatibility.
**IHTR vs. DHTR.
Table 8. 
Changes in laboratory indicators in haemolytic transfusion reactions [56].
Blood product Confirm ABO, Rh
Confirm other antigen types, if indicated
Blood bank laboratory Direct antiglobulin test (DAT)
Confirm ABO, RH, antibody screen and identification
Post-transfusion haemolysis check
Clinical laboratory Complete blood count, platelet count
Urinalysis for haemoglobin
Serum bilirubin, creatinine, urine quantitation, coagulation profile
DIC evaluation
Table 7. 
Type of laboratory tests and the location of their performance in the case of early transfusion reaction.
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Serological tests show positive DAT and the presence of all red blood cell anti-
bodies that were not detected prior to transfusion. This means that after transfusion 
of red blood cells, the production of alloantibodies directed to the antigen found on 
the transfused blood cells occurs.
Positive DAT with anti-IgG reagents or with anti-IgG and anti-C3 reagents is 
generally seen as two red blood cell populations. It has been observed that in some 
patients, the coating of blood cells includes not only transfused, but also autologous 
red blood cells. Positive DAT with anti-IgG and anti-C3d reagents may persist for 
several months [9].
Alloantibody testing should be performed in the intermediate antiglobulin test 
(IAT) and enzyme test. In both methods, in addition to the reference blood cells, 
the patient’s autologous blood cells should be included. Depending on the specific-
ity, alloantibodies responsible for the delayed transfusion reaction activate in char-
acteristic tests, for example, antibodies from the Rh system react in an enzymatic 
test, often also in anti-globulin testing. In contrast, anti-K, anti-Fya antibodies react 
in an anti-globulin test. Positive reactions with allogeneic blood cells are accompa-
nied by positive auto control of the patient’s red blood cells. Ness et al. [9] showed 
that the formation of warm autoantibodies after the onset of DHTR is relatively 
common. Approximately one-third of patients who were examined 25 days after 
the onset of the reaction presented a positive DAT due to autoantibodies with broad 
specificity [9]. The incidence of autoantibodies after DHTR may be even higher 
because autoantibodies may mimic the specificity of alloantibodies.
Usually, plasma alloantibodies are detectable at 4–7 days after the transfusion 
and reach maximum activity between 10 and 15 days after the transfusion. When 
examining recipient red blood cells using a diagnostic reagent with a specificity 
corresponding to alloantibodies detected in the patient, mixed agglutination is 
observed, which indicates the presence of two blood cell populations in the patient’s 
circulation. One of them, which does not react with diagnostic antibodies, is the 
recipient’s autologous blood cells, the other population is antigenically incompatible 
transfused donor cells, not yet removed from the recipient’s circulation.
10. Treatment of transfusion haemolytic reactions
Treatment of early haemolytic transfusion reactions depends mainly on the 
patient’s condition, which must be closely monitored. It is most important to 
observe the clinical symptoms of the recipient and stop the blood transfusion at the 
right moment. Particular attention should be paid to the patient’s circulation. In the 
event of a marked decrease in blood pressure, make-up fluids should be transfused 
and pressure amines should be administered. However, it is important to avoid 
overloading the circulation with fluids, especially in patients with heart or kidney 
failure. Catheterisation of the pulmonary artery helps to monitor the situation.
In some cases, an exchange transfusion should be considered, bearing in mind 
that the haemolysis intensity depends mainly on the volume of incompatible blood 
transfused. For exchange transfusion, red blood cells without an antigen should be 
used against which the patient has developed alloantibodies. The decision to carry 
it out must be balanced and the course carefully monitored. It should be empha-
sised that in patients with an early reaction due to ABO incompatibility, exchange 
transfusion may reduce the risk of serious complications or death. For patients 
with ongoing haemorrhage choosing a blood for transfusion may be difficult. 
However, it should be remembered that these difficulties must not cause risk of 
haemorrhage. Often the way out of this situation is transfusion of O RhD negative 
red blood cells.
Human Blood Group Systems
16
The prevention of renal failure is aided by an early prevention of hypotension. 
A fluid balance should be maintained, the use of dehydrating agents (mannitol and 
furosemide) is helpful, but their oliguria should be closely monitored. Low doses of 
dopamine (1–5 μg/kg/min) may be used to maintain renal circulation, but this may 
not be effective.
Treatment and prevention of DIC during haemolytic transfusion reaction is 
controversial. Heparin is recommended because it additionally acts as an inhibitor 
of the complement activity and limits haemolysis. However, there is a danger of 
bleeding. Another method of treating early haemolytic transfusion reaction is to use 
a high dose of 0.4/kg intravenous immunoglobulin per 24 h after blood transfusion.
Delayed haemolytic transfusion reactions are well tolerated by most patients. 
Additional fluid and diuretic therapy are usually not necessary. Depending on the 
severity of the anaemia, transfusion of blood components should be avoided until 
the antibodies responsible for the reaction have been identified and the appropri-
ate selection of blood cells has been made. Attempts have been made to use high 
doses of intravenous immunoglobulins to prevent haemolytic reactions in patients 
who have been immunised for winter and for whom compatible red blood cells 
have not been selected [63]. The main procedure for subsequent transfusions is to 
select red cells that do not contain the antigen for which all antibodies have been 
detected. Table 9 summarises the treatment options used in haemolytic transfusion 
reactions.
11. Prevention of haemolytic transfusion reactions
Data on the incidence of haemolytic transfusion reactions vary from country to 
country and change over time. There are several causes. One of them was the use of 
improved techniques for detecting clinically relevant alloantibodies, which reduce 
the number of haemolytic transfusion reactions observed in blood recipients. 
In addition, the widespread introduction of automation and computerisation to 
Therapeutic intervention Indication Typical dose
Hydration Prevent renal impairment
Maintain urine output
>100 ml/h
Normal saline and/or 5% dextrose 
200 ml/m2/h
Alkalinisation of urine Prevent renal impairment
Maintain urine pH > 7.5
NaH2CO3 40–70 mEq
Diuresis Prevent renal impairment Mannitol 20% 100 ml/m2
Furosemide 40–80 mg
Vasodilation Increase renal blood flow Dopamine 1–5 μg/kg/min
Anticoagulant Treat DIC Heparin 5–10 u/kg/h
Red cells exchange transfusion Decrease load of 
incompatible red cells
Exchange of one estimated red 
cells mass
Plasma or platelet transfusion Treat haemorrhagic 
complications of DIC
Platelet—1 unit platelet/10 kg or 1 
unit apheresis platelet
FFP—10 ml/kg
Intravenous immunoglobulin (not 
standard therapy)
Prevent extravascular 
haemolysis
0.4 mg/kg
DIC—disseminated intravascular coagulation; FFP—fresh frozen plasma.
Table 9. 
Therapeutic options in haemolytic transfusion reactions [1].
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pre-transfusion studies, which significantly limits the possibility of errors in serol-
ogy laboratories and blood banks.
The above improvements, however, did not significantly affect the elimination 
of mistakes made in hospitals leading to transfusion of inappropriate blood to 
the patient. These include, among others, errors in collecting blood samples from 
patients and blood transfusions to a wrong patient. These errors are the most com-
mon cause of ABO incompatible transfusions, threatening the patient’s life.
The introduction of haemovigilance transfusiological surveillance systems has 
enabled the analysis of all fatal and severe transfusion reactions. It allows to identify 
malfunctioning procedures leading to transfusion reactions. It enforces the intro-
duction of procedures eliminating further errors.
12. Summary
Preventing haemolytic transfusion reactions by focusing on advances in serol-
ogy and transfusion medicine has significantly reduced their incidence. Progress in 
understanding reaction pathophysiology has helped clinically assess patients and 
treat them effectively. It is possible that technological progress enabling modifica-
tion of red blood cells and the use of red blood cell substitutes will significantly 
change transfusion practice in the future and eliminate the occurrence of haemo-
lytic transfusion reactions. But until then, HTRs will remain the most important 
adverse post-transfusion reaction.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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